Investigation of Fat Metabolism during Antiobesity Interventions by Magnetic Resonance Imaging and Spectroscopy.

Magnetic resonance insights Pub Date : 2014-11-30 eCollection Date: 2014-01-01 DOI:10.4137/MRI.S19362

Arunima Pola, Suresh Anand Sadananthan, Venkatesh Gopalan, Min-Li Sandra Tan, Terry Yew Keong, Zhihong Zhou, Seigo Ishino, Yoshihide Nakano, Masanori Watanabe, Takashi Horiguchi, Tomoyuki Nishimoto, Bin Zhu, S Sendhil Velan

{"title":"Investigation of Fat Metabolism during Antiobesity Interventions by Magnetic Resonance Imaging and Spectroscopy.","authors":"Arunima Pola, Suresh Anand Sadananthan, Venkatesh Gopalan, Min-Li Sandra Tan, Terry Yew Keong, Zhihong Zhou, Seigo Ishino, Yoshihide Nakano, Masanori Watanabe, Takashi Horiguchi, Tomoyuki Nishimoto, Bin Zhu, S Sendhil Velan","doi":"10.4137/MRI.S19362","DOIUrl":null,"url":null,"abstract":"<p><p>The focus of current treatments for obesity is to reduce the body weight or visceral fat, which requires longer duration to show effect. In this study, we investigated the short-term changes in fat metabolism in liver, abdomen, and skeletal muscle during antiobesity interventions including Sibutra mine treatment and diet restriction in obese rats using magnetic resonance imaging, magnetic resonance spectroscopy, and blood chemistry. Sibutramine is an antiobesity drug that results in weight loss by increasing satiety and energy expenditure. The Sibutramine-treated rats showed reduction of liver fat and intramyocellular lipids on day 3. The triglycerides (TG) decreased on day 1 and 3 compared to baseline (day 0). The early response/nonresponse in different fat depots will permit optimization of treatment for better clinical outcome rather than staying with a drug for longer periods. </p>","PeriodicalId":74096,"journal":{"name":"Magnetic resonance insights","volume":"7 ","pages":"33-40"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251539/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magnetic resonance insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/MRI.S19362","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The focus of current treatments for obesity is to reduce the body weight or visceral fat, which requires longer duration to show effect. In this study, we investigated the short-term changes in fat metabolism in liver, abdomen, and skeletal muscle during antiobesity interventions including Sibutra mine treatment and diet restriction in obese rats using magnetic resonance imaging, magnetic resonance spectroscopy, and blood chemistry. Sibutramine is an antiobesity drug that results in weight loss by increasing satiety and energy expenditure. The Sibutramine-treated rats showed reduction of liver fat and intramyocellular lipids on day 3. The triglycerides (TG) decreased on day 1 and 3 compared to baseline (day 0). The early response/nonresponse in different fat depots will permit optimization of treatment for better clinical outcome rather than staying with a drug for longer periods.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

通过磁共振成像和光谱学研究抗肥胖干预期间的脂肪代谢。

目前治疗肥胖症的重点是减轻体重或减少内脏脂肪，这需要较长的时间才能显现效果。在这项研究中，我们利用磁共振成像、磁共振波谱和血液化学等方法，研究了肥胖大鼠在接受西布曲明治疗和限制饮食等抗肥胖干预措施期间，肝脏、腹部和骨骼肌中脂肪代谢的短期变化。西布曲明是一种抗肥胖药物，可通过增加饱腹感和能量消耗来减轻体重。西布曲明治疗的大鼠在第 3 天显示肝脏脂肪和细胞内脂类减少。与基线（第 0 天）相比，甘油三酯（TG）在第 1 天和第 3 天均有所下降。对不同脂肪层的早期反应/无应答将允许优化治疗，以获得更好的临床效果，而不是长期服用一种药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Magnetic resonance insights

自引率

0.00%

发文量